The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the drug. The US regulator ...

The fund outperformed its benchmark and peers for the final quarter and full year 2024, driven by positive stock selection.

Two one-shot doses of 4D-150 are being tested in the study and compared to Eylea. The high dose of the gene therapy – which is designed to express both aflibercept and an RNA interference (RNAi ...

Bayer’s consumer health business benefits from a narrow economic moat, largely because of its strong brand power. Consumers continue to pay a premium for Aspirin, Aleve, and other over-the-counter ...

Our manufacturing innovation center can produce 2,500 doses of RGX-202 per year ... which met its primary pivotal endpoint with high statistical significance. Patients treated with 121 achieved ...

A new large-scale study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators provides the strongest ...

An appeals court has upheld a District Court’s denial of a preliminary injunction for Amgen’s (AMGN) Eylea biosimilar, which UBS analyst Trung ...

had infringed on U.S. Patent 11,084,865, claimed to cover a vial containing Eylea. As a result of the ruling, Amgen, which produces a biosimilar for Eylea, saw its shares increase by as much as 0.5%.